Evidence map›Paper›PMID 28894558›Full record

ArticleMediterranean journal of hematology and infectious diseases2017

EBV and HHV-6 Circulating Subtypes in People Living with HIV in Burkina Faso, Impact on CD4 T cell count and HIV Viral Load.

Lassina Traore, Ouéogo Nikiema, Abdoul Karim Ouattara, Tegwindé Rébéca Compaore, Serge Théophile Soubeiga, Birama Diarra, Dorcas Obiri-Yeboah, Pegdwendé Abel Sorgho, Florencia Wendkuuni Djigma, Cyrille Bisseye and 2 more

Open access · goldAbstract read
In one paragraph

Article in Mediterranean journal of hematology and infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Lassina TraoreBiomolecular Research Center Pietro Annigoni (CERBA).
Ouéogo NikiemaBiomolecular Research Center Pietro Annigoni (CERBA).
Abdoul Karim OuattaraBiomolecular Research Center Pietro Annigoni (CERBA).
Tegwindé Rébéca CompaoreBiomolecular Research Center Pietro Annigoni (CERBA).
Serge Théophile SoubeigaBiomolecular Research Center Pietro Annigoni (CERBA).
Birama DiarraBiomolecular Research Center Pietro Annigoni (CERBA).
Dorcas Obiri-YeboahDeparment of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Ghana.
Pegdwendé Abel SorghoBiomolecular Research Center Pietro Annigoni (CERBA).
Florencia Wendkuuni DjigmaBiomolecular Research Center Pietro Annigoni (CERBA).
Cyrille BisseyeBiomolecular Research Center Pietro Annigoni (CERBA).
Albert Théophane YonliBiomolecular Research Center Pietro Annigoni (CERBA).
Jacques SimporeBiomolecular Research Center Pietro Annigoni (CERBA).
Université Ouaga II · BFUniversity of Cape Coast · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epstein Barr Virus (EBV) and Human Herpes Virus 6 (HHV-6) are responsible for severe diseases, particularly in immunocompromised persons. There is limited data of the infection of these opportunistic viruses in Burkina Faso. The purpose of this study was to characterize EBV and HHV-6 subtypes and to assess their impact on CD4 T cell count, HIV-1 viral load and antiretroviral treatment in people living with HIV-1. The study population consisted of 238 HIV-positive patients with information on the CD4 T cell count, HIV-1 viral load and HAART. Venous blood samples collected in EDTA tubes were used for EBV and HHV-6 Real Time PCR subtyping. An infection rate of 6.7% (16/238) and 7.1% (17/238) were found respectively for EBV and HHV-6 in the present study. Among EBV infections, similar prevalence was noted for both subtypes (3.9% (9/238) for EBV-1 vs 4.6% (11/238) for EBV-2) with 2.1% (5/238) of co-infection. HHV-6A infection represented 6.3% (15/238) of the study population against 5.0% (12/238) for HHV-6B. EBV-2 infection was significantly higher in patients with CD4 T cell count ≥ 500 compared to those with CD4 T cell count less than 500 cells (1.65% vs 8.56%, p = 0,011). The prevalence of EBV and HHV-6 infections was almost similar in HAART-naive and HAART-experienced patients. The present study provides information on the prevalence of EBV and HHV-6 subtypes in people living with HIV-1 in Burkina Faso. The study also suggests that HAART treatment has no effect on infection with these opportunistic viruses in people living with HIV-1.

Indexed as

and treatmentCD4 T cell countEBVHHV-6HIV-1subtypeviral load

Identifiers

PMID28894558
PMCPMC5584768
OpenAlexW2746221158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.